comparemela.com

Latest Breaking News On - Office of therapeutic biologics - Page 6 : comparemela.com

FDA approves 1st biosimilar to treat multiple sclerosis | The Highland County Press

The U.S. Food and Drug Administration recently approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).

MS treatment: FDA-approved biosimilar could bring down costs

The Food and Drug Administration has recently announced the approval of the first biosimilar treatment for multiple sclerosis, called Tyruko, which provides a potentially more cost-effective alternative to Tysabri.

FDA Approves Biosimilar Tyruko for Multiple Sclerosis, Crohn Disease

The Food and Drug Administration has approved Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab).

Natalizumab-sztn Receives FDA Approval as First Biosimilar for Multiple Sclerosis

The approval was based on evidence showing no clinically meaningful differences between natalizumab-sztn and the reference drug in terms of safety, purity, and potency.

Tyruko, first Tysabri biosimilar, cleared in US to treat relapsing MS | Multiple Sclerosis News Today

Tyruko, first Tysabri biosimilar, cleared in US to treat relapsing MS | Multiple Sclerosis News Today
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.